Cullinan Therapeutics (CGEM) Financials

$7.89 +0.28 (+3.68%)

Closing price 04/17/2025 04:00 PM Eastern

Extended Trading

$7.88 0.00 (-0.06%)

As of 04/17/2025 05:14 PM Eastern

Annual Income Statements for Cullinan Therapeutics

This table shows Cullinan Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Net Income / (Loss) Attributable to Common Shareholders	111	-153	-167
Consolidated Net Income / (Loss)	109	-155	-168
Net Income / (Loss) Continuing Operations	109	-155	-168
Total Pre-Tax Income	151	-169	-167
Total Operating Income	145	-191	-197
Total Gross Profit	0.00	0.00	0.00
Total Revenue	0.00	0.00	0.00
Total Cost of Revenue	0.00	0.00	0.00
Total Operating Expenses	-145	191	197
Selling, General & Admin Expense	40	42	54
Research & Development Expense	92	148	143
Total Other Income / (Expense), net	6.67	22	29
Interest & Investment Income	6.61	22	30
Other Income / (Expense), net	0.06	0.24	-0.20
Income Tax Expense	42	-14	0.12
Net Income / (Loss) Attributable to Noncontrolling Interest	-2.02	-1.94	-0.19
Basic Earnings per Share	$2.46	($35.33)	$0.00
Weighted Average Basic Shares Outstanding	45.16M	42.16M	0.00
Diluted Earnings per Share	$2.38	($35.33)	$0.00
Weighted Average Diluted Shares Outstanding	46.64M	42.16M	0.00
Weighted Average Basic & Diluted Shares Outstanding	39.33M	43.07M	58.51M

This table shows Cullinan Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Net Income / (Loss) Attributable to Common Shareholders	-25	-27	-58	-32	-39	-24	-37	-42	-41	-48
Consolidated Net Income / (Loss)	-25	-27	-58	-32	-39	-26	-37	-42	-41	-48
Net Income / (Loss) Continuing Operations	-25	-27	-58	-32	-39	-26	-37	-42	-41	-48
Total Pre-Tax Income	-27	-29	-58	-32	-39	-40	-37	-42	-41	-48
Total Operating Income	-30	-33	-63	-38	-45	-45	-43	-50	-49	-55
Total Operating Expenses	30	33	63	38	45	45	43	50	49	55
Selling, General & Admin Expense	10	11	11	10	11	11	12	14	13	15
Research & Development Expense	20	21	52	27	34	35	31	36	36	40
Total Other Income / (Expense), net	2.35	3.66	4.62	5.39	6.06	5.80	5.65	8.00	8.30	7.52
Interest & Investment Income	2.35	3.36	4.51	5.32	5.88	5.92	5.69	8.07	8.38	7.51
Other Income / (Expense), net	0.00	0.30	0.11	0.07	0.18	-0.12	-0.04	-0.07	-0.09	0.01
Basic Earnings per Share	($0.54)	($0.63)	($1.42)	($0.82)	($0.91)	($32.18)	($0.86)	($0.75)	($0.69)	$2.30
Weighted Average Basic Shares Outstanding	45.61M	45.16M	40.68M	39.95M	42.73M	42.16M	43.01M	55.05M	58.34M	0.00
Diluted Earnings per Share	($0.54)	($0.58)	($1.42)	($0.82)	($0.91)	($32.18)	($0.86)	($0.75)	($0.69)	$2.30
Weighted Average Diluted Shares Outstanding	45.61M	46.64M	40.68M	39.95M	42.73M	42.16M	43.01M	55.05M	58.34M	0.00
Weighted Average Basic & Diluted Shares Outstanding	45.77M	39.33M	40.68M	42.73M	42.78M	43.07M	57.63M	57.98M	58.23M	58.51M

This table details how cash moves in and out of Cullinan Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Net Change in Cash & Equivalents	96	-58	-15
Net Cash From Operating Activities	-127	-134	-145
Net Cash From Continuing Operating Activities	-127	-134	-145
Net Income / (Loss) Continuing Operations	109	-155	-168
Consolidated Net Income / (Loss)	109	-155	-168
Depreciation Expense	0.09	0.31	0.31
Amortization Expense	1.29	-10	-15
Non-Cash Adjustments To Reconcile Net Income	-248	31	38
Changes in Operating Assets and Liabilities, net	11	-0.34	-0.39
Net Cash From Investing Activities	249	36	-136
Net Cash From Continuing Investing Activities	249	36	-136
Purchase of Property, Plant & Equipment	-1.13	-0.21	0.00
Purchase of Investments	-378	-373	-721
Sale and/or Maturity of Investments	353	409	585
Net Cash From Financing Activities	-26	41	266
Net Cash From Continuing Financing Activities	-26	41	266
Repayment of Debt	-2.20	0.00	0.00
Payment of Dividends	-33	0.00	-4.45
Issuance of Preferred Equity	2.38	1.83	0.00
Issuance of Common Equity	6.02	39	271
Other Financing Activities, net	1.15	0.00	0.00
Cash Income Taxes Paid	38	-4.43	-2.27

This table details how cash moves in and out of Cullinan Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Net Change in Cash & Equivalents	-111	-87	-34	20	-77	34	-24	41	-13	-19
Net Cash From Operating Activities	-54	-25	-51	-31	-34	-18	-38	-36	-34	-37
Net Cash From Continuing Operating Activities	-54	-25	-51	-31	-34	-18	-38	-36	-34	-37
Net Income / (Loss) Continuing Operations	-25	-27	-58	-32	-39	-26	-37	-42	-41	-48
Consolidated Net Income / (Loss)	-25	-27	-58	-32	-39	-26	-37	-42	-41	-48
Depreciation Expense	0.01	0.06	0.07	0.08	0.08	0.08	0.08	0.08	0.08	0.08
Amortization Expense	0.16	-0.60	-1.37	-	-	-3.62	-3.31	-	-	-3.51
Non-Cash Adjustments To Reconcile Net Income	5.26	7.69	7.26	4.40	12	7.65	8.23	3.50	16	9.63
Changes in Operating Assets and Liabilities, net	-35	-5.01	1.18	-4.65	-0.18	3.31	-5.90	-1.15	1.84	4.82
Net Cash From Investing Activities	-58	-29	15	12	-43	51	13	-185	20	16
Net Cash From Continuing Investing Activities	-58	-29	15	12	-43	51	13	-185	20	16
Purchase of Investments	-124	-160	-89	-81	-137	-66	-131	-325	-97	-168
Sale and/or Maturity of Investments	61	133	104	94	94	117	144	140	117	184
Net Cash From Financing Activities	1.43	-33	1.79	39	0.11	0.25	1.09	262	1.33	1.58
Net Cash From Continuing Financing Activities	1.43	-33	1.79	39	0.11	0.25	1.09	262	1.33	1.58
Issuance of Common Equity	1.43	0.19	-0.04	0.21	0.11	39	1.09	3.34	1.98	264
Other Financing Activities, net	-	-	-	-	-	-38	-	-	-	-263

This table presents Cullinan Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Total Assets	561	484	622
Total Current Assets	474	480	415
Cash & Equivalents	156	98	83
Short-Term Investments	311	369	316
Prepaid Expenses	7.18	13	16
Plant, Property, & Equipment, net	1.17	0.99	0.68
Total Noncurrent Assets	85	3.00	206
Long-Term Investments	81	0.00	204
Other Noncurrent Operating Assets	4.59	3.00	2.03
Total Liabilities & Shareholders' Equity	561	484	622
Total Liabilities	26	30	31
Total Current Liabilities	22	28	31
Accounts Payable	2.66	2.49	1.68
Accrued Expenses	14	24	28
Other Current Liabilities	1.42	1.44	1.30
Total Noncurrent Liabilities	3.59	2.15	0.85
Other Noncurrent Operating Liabilities	3.59	2.15	0.85
Commitments & Contingencies	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	535	454	590
Total Preferred & Common Equity	535	454	590
Preferred Stock	0.00	0.00	0.00
Total Common Equity	535	454	590
Common Stock	585	655	959
Retained Earnings	-48	-201	-368
Accumulated Other Comprehensive Income / (Loss)	-2.60	-0.13	-0.13
Noncontrolling Interest	0.00	0.19	0.00

This table presents Cullinan Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024
Total Assets	617	515	522	495	449	681	653
Total Current Assets	582	399	498	477	446	678	592
Cash & Equivalents	243	122	142	65	74	115	102
Short-Term Investments	333	269	350	402	359	547	476
Prepaid Expenses	6.12	8.33	6.44	10	13	15	14
Plant, Property, & Equipment, net	0.79	1.24	1.16	1.07	0.91	0.84	0.76
Total Noncurrent Assets	34	115	23	17	2.80	2.58	60
Long-Term Investments	29	110	19	14	0.00	0.00	58
Other Noncurrent Operating Assets	4.96	4.28	3.96	3.38	2.80	2.58	2.48
Total Liabilities & Shareholders' Equity	617	515	522	495	449	681	653
Total Liabilities	31	29	22	26	24	25	25
Total Current Liabilities	27	26	20	23	22	23	24
Accounts Payable	1.52	2.03	2.49	0.95	3.71	1.56	2.12
Accrued Expenses	14	18	16	21	17	21	21
Other Current Liabilities	0.70	1.55	1.65	1.55	1.33	1.22	1.26
Total Noncurrent Liabilities	3.99	3.17	2.73	2.45	1.84	1.52	1.19
Noncurrent Deferred Revenue	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Other Noncurrent Operating Liabilities	3.99	3.17	2.73	2.45	1.84	1.52	1.19
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	586	486	500	469	426	656	628
Total Preferred & Common Equity	586	486	500	469	426	656	628
Preferred Stock	-	-	0.00	0.00	0.00	0.00	0.00
Total Common Equity	586	486	500	469	426	656	628
Common Stock	611	593	639	647	664	937	947
Retained Earnings	-21	-106	-138	-177	-238	-280	-321
Accumulated Other Comprehensive Income / (Loss)	-3.93	-1.24	-1.63	-1.05	-0.33	-0.48	0.97
Noncontrolling Interest	0.00	0.00	0.00	0.00	0.00	0.00	0.00

This table displays calculated financial ratios and metrics derived from Cullinan Therapeutics' official financial filings.

Metric	2022	2023	2024
Growth Metrics	-	-	-
Revenue Growth	-100.00%	0.00%	0.00%
EBITDA Growth	315.13%	-237.38%	-5.77%
EBIT Growth	312.92%	-231.89%	-3.28%
NOPAT Growth	319.44%	-228.15%	-3.05%
Net Income Growth	261.81%	-242.04%	-8.04%
EPS Growth	0.00%	-1,584.45%	100.00%
Operating Cash Flow Growth	-191.63%	-6.01%	-8.21%
Free Cash Flow Firm Growth	315.58%	-219.36%	-3.13%
Invested Capital Growth	-139.48%	-0.21%	0.63%
Revenue Q/Q Growth	0.00%	0.00%	0.00%
EBITDA Q/Q Growth	2.36%	-8.84%	-4.60%
EBIT Q/Q Growth	1.42%	-7.49%	-5.03%
NOPAT Q/Q Growth	-26.96%	-7.23%	-5.10%
Net Income Q/Q Growth	6.97%	0.97%	-15.18%
EPS Q/Q Growth	0.00%	-847.19%	100.00%
Operating Cash Flow Q/Q Growth	-8.40%	4.86%	-14.59%
Free Cash Flow Firm Q/Q Growth	-30.94%	-0.68%	-2.84%
Invested Capital Q/Q Growth	31.67%	-18.05%	-59.78%
Profitability Metrics	-	-	-
Gross Margin	0.00%	0.00%	0.00%
EBITDA Margin	0.00%	0.00%	0.00%
Operating Margin	0.00%	0.00%	0.00%
EBIT Margin	0.00%	0.00%	0.00%
Profit (Net Income) Margin	0.00%	0.00%	0.00%
Tax Burden Percent	72.16%	91.65%	100.07%
Interest Burden Percent	104.57%	88.67%	84.95%
Effective Tax Rate	27.84%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%
Return on Equity (ROE)	22.74%	-31.37%	-32.10%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	0.00%	0.00%	0.00%
Return on Assets (ROA)	0.00%	0.00%	0.00%
Return on Common Equity (ROCE)	22.73%	-31.36%	-32.09%
Return on Equity Simple (ROE_SIMPLE)	20.41%	-34.19%	-28.39%
Net Operating Profit after Tax (NOPAT)	104	-134	-138
NOPAT Margin	0.00%	0.00%	0.00%
Net Nonoperating Expense Percent (NNEP)	0.98%	-4.20%	-5.55%
Return On Investment Capital (ROIC_SIMPLE)	-	-29.47%	-23.35%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	0.00%	0.00%	0.00%
R&D to Revenue	0.00%	0.00%	0.00%
Operating Expenses to Revenue	0.00%	0.00%	0.00%
Earnings before Interest and Taxes (EBIT)	145	-191	-197
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	146	-201	-212
Valuation Ratios	-	-	-
Price to Book Value (P/BV)	0.90	0.96	1.20
Price to Tangible Book Value (P/TBV)	0.90	0.96	1.20
Price to Revenue (P/Rev)	0.00	0.00	0.00
Price to Earnings (P/E)	4.34	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%
Earnings Yield	23.03%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	0.00	0.00	0.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00
Leverage & Solvency	-	-	-
Debt to Equity	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00
Financial Leverage	-1.02	-1.03	-1.03
Leverage Ratio	1.04	1.06	1.06
Compound Leverage Factor	1.09	0.94	0.90
Debt to Total Capital	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.04%	0.00%
Common Equity to Total Capital	100.00%	99.96%	100.00%
Debt to EBITDA	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00
Altman Z-Score	12.80	7.87	12.38
Noncontrolling Interest Sharing Ratio	0.04%	0.02%	0.02%
Liquidity Ratios	-	-	-
Current Ratio	21.09	17.07	13.53
Quick Ratio	20.77	16.60	13.02
Cash Flow Metrics	-	-	-
Free Cash Flow to Firm (FCFF)	112	-134	-138
Operating Cash Flow to CapEx	-12,155.85%	-64,555.29%	0.00%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00
Efficiency Ratios	-	-	-
Asset Turnover	0.00	0.00	0.00
Accounts Receivable Turnover	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00
Fixed Asset Turnover	0.00	0.00	0.00
Accounts Payable Turnover	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-
Invested Capital	-13	-13	-13
Invested Capital Turnover	0.00	0.00	0.00
Increase / (Decrease) in Invested Capital	-7.66	-0.03	0.08
Enterprise Value (EV)	-65	-31	106
Market Capitalization	483	436	709
Book Value per Share	$11.69	$10.61	$10.14
Tangible Book Value per Share	$11.69	$10.61	$10.14
Total Capital	535	454	590
Total Debt	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00
Net Debt	-548	-467	-603
Capital Expenditures (CapEx)	1.04	0.21	0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-15	-15	-15
Debt-free Net Working Capital (DFNWC)	452	452	384
Net Working Capital (NWC)	452	452	384
Net Nonoperating Expense (NNE)	-4.81	21	30
Net Nonoperating Obligations (NNO)	-548	-467	-603
Total Depreciation and Amortization (D&A)	1.39	-9.84	-15
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	0.00%	0.00%
Debt-free Net Working Capital to Revenue	0.00%	0.00%	0.00%
Net Working Capital to Revenue	0.00%	0.00%	0.00%
Earnings Adjustments	-	-	-
Adjusted Basic Earnings per Share	$2.46	($3.69)	$0.00
Adjusted Weighted Average Basic Shares Outstanding	45.16M	41.55M	0.00
Adjusted Diluted Earnings per Share	$2.38	($3.69)	$0.00
Adjusted Weighted Average Diluted Shares Outstanding	46.64M	41.55M	0.00
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	39.33M	43.07M	58.51M
Normalized Net Operating Profit after Tax (NOPAT)	-95	-134	-138
Normalized NOPAT Margin	0.00%	0.00%	0.00%
Pre Tax Income Margin	0.00%	0.00%	0.00%
Debt Service Ratios	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00
Payout Ratios	-	-	-
Dividend Payout Ratio	30.48%	0.00%	-2.65%
Augmented Payout Ratio	30.48%	0.00%	-2.65%

This table displays calculated financial ratios and metrics derived from Cullinan Therapeutics' official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Growth	-69.74%	4.31%	-101.74%	-115.59%	-51.97%	-49.60%	27.66%	-33.55%	-8.64%	-18.98%
EBIT Growth	-61.97%	5.92%	-91.84%	-115.68%	-51.39%	-41.14%	31.31%	-33.47%	-8.61%	-20.70%
NOPAT Growth	-61.99%	5.06%	-92.17%	-115.15%	-52.00%	-39.49%	31.50%	-33.03%	-7.98%	-21.02%
Net Income Growth	-36.32%	20.81%	-350.99%	-118.51%	-57.42%	5.63%	35.78%	-30.47%	-3.51%	-86.39%
EPS Growth	-35.00%	0.00%	-425.93%	-121.75%	-68.52%	-5,448.28%	39.44%	8.54%	24.18%	107.15%
Operating Cash Flow Growth	-415.15%	-64.68%	-132.78%	-21.97%	37.19%	27.43%	25.00%	-17.05%	0.01%	-102.01%
Free Cash Flow Firm Growth	88.43%	46.67%	50.80%	-128.84%	-2,551.35%	-109.71%	-112.46%	39.10%	6.50%	-21.39%
Invested Capital Growth	-19,337.00%	-139.48%	-248.43%	78.10%	42.00%	-0.21%	52.59%	42.20%	26.58%	0.63%
Revenue Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Q/Q Growth	-112.32%	-10.98%	-94.66%	41.43%	-20.10%	-9.25%	5.87%	-8.13%	2.31%	-19.66%
EBIT Q/Q Growth	-112.43%	-8.55%	-93.90%	40.09%	-20.05%	-1.20%	5.63%	-16.42%	2.31%	-12.46%
NOPAT Q/Q Growth	-111.99%	-9.55%	-92.46%	40.08%	-20.31%	-0.53%	5.49%	-16.37%	2.34%	-12.68%
Net Income Q/Q Growth	-114.30%	-8.83%	-114.64%	44.59%	-21.63%	34.76%	-46.07%	-12.55%	3.49%	-17.47%
EPS Q/Q Growth	-114.32%	-7.41%	-144.83%	42.25%	-10.98%	-3,436.26%	-59.26%	12.79%	8.00%	433.33%
Operating Cash Flow Q/Q Growth	-113.82%	54.04%	-104.13%	39.20%	-10.11%	46.89%	-110.95%	5.11%	5.93%	-7.28%
Free Cash Flow Firm Q/Q Growth	-100.66%	-911.85%	-18.65%	-261.30%	38.87%	19.97%	-20.20%	-3.56%	6.15%	-3.91%
Invested Capital Q/Q Growth	61.18%	31.67%	-17.86%	29.94%	-2.79%	-18.05%	44.23%	14.59%	-30.57%	-59.78%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBIT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Profit (Net Income) Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Tax Burden Percent	90.80%	93.58%	100.00%	100.00%	100.00%	64.41%	100.00%	100.00%	100.00%	100.25%
Interest Burden Percent	92.10%	89.59%	92.80%	85.82%	86.95%	87.02%	86.77%	83.89%	82.87%	86.35%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	19.79%	22.74%	14.13%	-25.78%	-29.69%	-31.37%	-29.47%	-24.94%	-26.53%	-32.10%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Assets (ROA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Common Equity (ROCE)	19.75%	22.73%	14.12%	-25.78%	-29.69%	-31.36%	-29.47%	-24.94%	-26.53%	-32.09%
Return on Equity Simple (ROE_SIMPLE)	17.42%	0.00%	13.17%	-28.49%	-33.41%	0.00%	-31.55%	-21.96%	-23.17%	0.00%
Net Operating Profit after Tax (NOPAT)	-21	-23	-44	-26	-32	-32	-30	-35	-34	-39
NOPAT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Nonoperating Expense Percent (NNEP)	-0.77%	-0.87%	-3.12%	-1.01%	-1.38%	1.24%	-1.55%	-1.20%	-1.14%	-1.70%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-7.01%	-	-	-	-6.53%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings before Interest and Taxes (EBIT)	-30	-32	-63	-38	-45	-46	-43	-50	-49	-55
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-30	-33	-64	-37	-45	-49	-46	-50	-49	-58
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	1.00	0.90	0.83	0.85	0.82	0.96	1.72	1.53	1.55	1.20
Price to Tangible Book Value (P/TBV)	1.00	0.90	0.83	0.85	0.82	0.96	1.72	1.53	1.55	1.20
Price to Revenue (P/Rev)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Earnings (P/E)	5.54	4.34	6.16	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	18.04%	23.03%	16.24%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-1.02	-1.02	-1.01	-1.05	-1.03	-1.03	-1.03	-1.01	-1.02	-1.03
Leverage Ratio	1.04	1.04	1.05	1.08	1.05	1.06	1.06	1.04	1.05	1.06
Compound Leverage Factor	0.96	0.93	0.98	0.92	0.92	0.92	0.92	0.87	0.87	0.91
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.04%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%	100.00%	100.00%	99.96%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	12.15	11.76	8.41	11.83	9.26	8.86	18.60	24.46	23.04	13.13
Noncontrolling Interest Sharing Ratio	0.20%	0.04%	0.08%	0.01%	0.00%	0.02%	0.00%	0.00%	0.00%	0.02%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	21.47	21.09	15.25	25.32	20.33	17.07	20.33	28.87	24.46	13.53
Quick Ratio	21.24	20.77	14.93	24.99	19.90	16.60	19.75	28.22	23.88	13.02
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-1.50	-15	-18	-65	-40	-32	-38	-40	-37	-39
Operating Cash Flow to CapEx	-21,654.58%	-2,832.54%	-32,073.58%	-63,277.55%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Accounts Receivable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	-19	-13	-15	-11	-11	-13	-7.35	-6.27	-8.19	-13
Invested Capital Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Increase / (Decrease) in Invested Capital	-19	-7.66	-26	39	8.08	-0.03	8.15	4.58	2.97	0.08
Enterprise Value (EV)	-21	-65	-99	-87	-93	-31	301	343	334	106
Market Capitalization	585	483	402	424	387	436	734	1,005	971	709
Book Value per Share	$12.85	$11.69	$12.35	$12.69	$10.97	$10.61	$9.88	$11.39	$10.83	$10.14
Tangible Book Value per Share	$12.85	$11.69	$12.35	$12.69	$10.97	$10.61	$9.88	$11.39	$10.83	$10.14
Total Capital	586	535	486	500	469	454	426	656	628	590
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-605	-548	-501	-510	-480	-467	-433	-662	-636	-603
Capital Expenditures (CapEx)	0.25	0.88	0.16	0.05	0.00	0.00	0.00	0.00	0.00	0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-21	-15	-18	-13	-13	-15	-9.22	-8.17	-10	-15
Debt-free Net Working Capital (DFNWC)	555	452	373	479	453	452	424	654	568	384
Net Working Capital (NWC)	555	452	373	479	453	452	424	654	568	384
Net Nonoperating Expense (NNE)	4.05	4.26	14	5.89	7.51	-6.28	7.25	7.01	6.36	9.11
Net Nonoperating Obligations (NNO)	-605	-548	-501	-510	-480	-467	-433	-662	-636	-603
Total Depreciation and Amortization (D&A)	0.17	-0.54	-1.30	0.08	0.08	-3.54	-3.23	0.08	0.08	-3.43
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Debt-free Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.54)	($0.63)	$0.00	($0.82)	($0.91)	($32.18)	($0.86)	($0.75)	($0.69)	$2.30
Adjusted Weighted Average Basic Shares Outstanding	45.61M	45.16M	40.68M	39.95M	42.73M	42.16M	43.01M	55.05M	58.34M	0.00
Adjusted Diluted Earnings per Share	($0.54)	($0.58)	$0.00	($0.82)	($0.91)	($32.18)	($0.86)	($0.75)	($0.69)	$2.30
Adjusted Weighted Average Diluted Shares Outstanding	45.61M	46.64M	40.68M	39.95M	42.73M	42.16M	43.01M	55.05M	58.34M	0.00
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	45.77M	39.33M	40.68M	42.73M	42.78M	43.07M	57.63M	57.98M	58.23M	58.51M
Normalized Net Operating Profit after Tax (NOPAT)	-21	-23	-44	-26	-32	-32	-30	-35	-34	-39
Normalized NOPAT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Pre Tax Income Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	30.48%	0.00%	0.00%	0.00%	0.00%	0.00%	-2.63%	-3.06%	-2.65%
Augmented Payout Ratio	0.00%	30.48%	0.00%	0.00%	0.00%	0.00%	0.00%	-2.63%	-3.06%	-2.65%

Frequently Asked Questions About Cullinan Therapeutics' Financials

When does Cullinan Therapeutics's fiscal year end?

According to the most recent income statement we have on file, Cullinan Therapeutics' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Cullinan Therapeutics' net income changed over the last 2 years?

Cullinan Therapeutics' net income appears to be on an upward trend, with a most recent value of -$167.58 million in 2024, falling from $109.20 million in 2022. The previous period was -$155.10 million in 2023.

What is Cullinan Therapeutics's operating income?

Cullinan Therapeutics's total operating income in 2024 was -$196.92 million, based on the following breakdown:

Total Gross Profit: $0.00
Total Operating Expenses: $196.92 million

How has Cullinan Therapeutics revenue changed over the last 2 years?

Over the last 2 years, Cullinan Therapeutics' total revenue changed from $0.00 in 2022 to $0.00 in 2024, a change of 0.0%.

How much debt does Cullinan Therapeutics have?

Cullinan Therapeutics' total liabilities were at $31.50 million at the end of 2024, a 4.0% increase from 2023, and a 20.7% increase since 2022.

How much cash does Cullinan Therapeutics have?

In the past 2 years, Cullinan Therapeutics' cash and equivalents has ranged from $83.01 million in 2024 to $156.15 million in 2022, and is currently $83.01 million as of their latest financial filing in 2024.

How has Cullinan Therapeutics' book value per share changed over the last 2 years?

Over the last 2 years, Cullinan Therapeutics' book value per share changed from 11.69 in 2022 to 10.14 in 2024, a change of -13.3%.

Related Companies

This page (NASDAQ:CGEM) was last updated on 4/19/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cullinan Therapeutics (CGEM) Financials

Frequently Asked Questions About Cullinan Therapeutics' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cullinan Therapeutics (CGEM) Financials

Annual Income Statements for Cullinan Therapeutics

Quarterly Income Statements for Cullinan Therapeutics

Annual Cash Flow Statements for Cullinan Therapeutics

Quarterly Cash Flow Statements for Cullinan Therapeutics

Annual Balance Sheets for Cullinan Therapeutics

Quarterly Balance Sheets for Cullinan Therapeutics

Annual Metrics and Ratios for Cullinan Therapeutics

Quarterly Metrics and Ratios for Cullinan Therapeutics

Frequently Asked Questions About Cullinan Therapeutics' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools